

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 61956

**Title:** Oncological group for the study of lung cancer of the Spanish society of radiation oncology clinical guidelines on radiotherapy for malignant pleural mesothelioma

**Reviewer's code:** 03092939

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Assistant Professor, Lecturer

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Spain

**Manuscript submission date:** 2020-12-24

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-08 06:03

**Reviewer performed review:** 2021-04-08 07:43

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

This paper is well-written and can interest authors. However, I would suggest the following points which may be considered before publication. -3. DIAGNOSIS AND TNM STAGING and 4. CLINICAL INDICATIONS BY TUMOR STAGE AND TREATMENT may be more summerized. -Please consider to include the recent phase 3 RCT data (Trovo M, et al. Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1368–76. -Typical case and dose constrain of postoperative RT after EPP may be helpful as well as post P/D. Please consider to provide them in a table and figure. Previous review which is already cited may be refered fo geneate this (Gomez DR, et al. J Thorac Oncol. 2019 Jul;14(7):1172–83. ). -7. RERADIATION and 8. FOLLOW-UPmay be removable. SALVAGE RADIOTHERAPY can be included in SBRT section.